Close Menu

MRSA

DxNA has acquired exclusive rights to run PathoGene's multiplexed Staphylococcus MRSA+ assay on DxNA's real-time PCR-based GeneStat platform, the companies said this week.

Cepheid's Xpert CT/NG assay for the detection and differentiation of Chlamydia trachomatis and Neisseria gonorrhoeae, launched in the US at the start of the year, has seen the greatest uptake of any new Xpert test since Xpert MRSA, President and CEO John Bishop

NEW YORK (GenomeWeb News) – A research team using whole-genome sequencing to track a form of methicillin-resistant Staphylococcus aureus found in livestock and humans has uncovered genetic evidence confirming animal-to-human transmission of the bug during at least one farm outbreak in De

Carpegen, a German company providing real-time PCR-based testing services to dental practices, this week unveiled a beta version of its benchtop, cartridge-based, sample-to-answer molecular diagnostics platform.

NEW YORK (GenomeWeb News) – In a study appearing online today in The Lancet Infectious Diseases, a UK team describes the whole-genome sequencing approach it used to assess

Finnish molecular diagnostics firm Abacus Diagnostica, fresh off winning a pair of key US patents covering its DNA testing technologies, plans to seek regulatory approval in the US next year for tests to detect Staphylococcus aureus and methicillin-resistant S.

Becton Dickinson said this week that its BD MAX MRSA molecular test has received a CLIA moderate complexity rating.

NEW YORK (GenomeWeb News) – Becton Dickinson segment BD Diagnostics said today its BD Max MRSA molecular test has received a Moderate Complexity rating under the Clinical Laboratory Improvement Amendments of 1988.

This story has been updated from a previous version to include information about BD's ongoing assay-development partnership with Diagenode.

NEW YORK (GenomeWeb News) – A Leerink Swann survey of diagnostic laboratories in Europe found that molecular-based testing continues to find traction with continued penetration strongest in methicillin-resistant Staphylococcus aureus testing and human papillomavirus testing.

Pages

A new analysis finds that nearly half the late-stage clinical trials sponsored by a US National Cancer Institute program influence patient care.

Technology Review reports that sickle cell patients are optimistic about gene editing to treat their disease, but are worried about how available it will be.

The owner of the GEDmatch website tells CBS12 he is considering charging law enforcement a fee to use the site.

In Nature this week: babies born by caesarean section are more likely to have altered gut microbiota profiles, and more.